Qiagen (QGEN) Agrees to EUR 46.50 Cash Takeover Offer by EQT XI
Qiagen (QGEN) accepted a EUR 46.50 per share cash takeover offer from EQT XI, valuing the company at EUR 10.8 billion. The bid is a 40.3% premium over Qiagen's pre-rumor closing price. Qiagen's GF Value is $50.01, with a GF Score of 75, indicating fair valuation and strong fundamentals. The deal is expected to close by mid-2027, subject to approvals.
How this was made
The 30-second read
Why it matters
The deal values Qiagen at roughly €10.8 bn, a 40% premium to recent trading levels, and is expected to close by mid‑2027 pending approvals.
Market read
The announcement is a material M&A event that will likely move Qiagen's stock toward the offer price and may trigger broader sector re‑pricing.
What to watch
Regulatory approvals and the minimum acceptance threshold could delay or derail the transaction.
Background
Qiagen, a Netherlands‑based leader in molecular biology solutions, is the target of a consortium led by EQT XI, with co‑investors Luxinva and CPP Investment Board Europe.
Ticker impact
Qiagen announced a voluntary all‑cash takeover offer at €46.50 per share, a 40% premium, representing a €10.8 bn valuation.
upward pressure as the market prices in the takeover premium
A definitive, premium‑filled acquisition offer creates immediate upside potential for shareholders.
Market effects
Potential consolidation in the molecular diagnostics space, prompting peers to reassess valuations.
European biotech M&A activity may see heightened interest following this high‑profile deal.
Large‑cap private‑equity interest in healthcare could influence global capital allocation trends.
Counterpoint
The premium may be insufficient if Qiagen's growth prospects improve under public ownership.
Key entities
- companyQiagen NV
Target of the cash takeover offer.
- private equity fundEQT XI
Lead investor in the acquisition consortium.
